NBTX
Nanobiotix S.A.
$35.88
+1.18%
$1.7B
No data for this timeframe.
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders2 funds
Inst. Value$534.6K
Inst. Activity1 buys / 0 sells
SEC Reports5
Press Releases10
Recent Activity
May 18, 2026
SEC
Nanobiotix announced Part 1 data from the CONVERGE Phase 2 trial of JNJ-1900 (NBTXR3) in stage 3 inoperable NSCLC, prese
6-K — Impact 7/10
Apr 20, 2026
SEC
Nanobiotix announced preclinical data showing that its Nanoprimer technology improves systemic bioavailability and reduc
6-K — Impact 6/10
Apr 7, 2026
SEC
Nanobiotix filed a routine 6-K disclosing its voting rights and share capital as of March 31, 2026, showing 48,517,630 s
6-K — Impact 2/10
Inst.
MORGAN STANLEY — DOUBLED
22,923 shares ($530.0K)
Inst.
MORGAN STANLEY — TRIM
2,378 shares ($44.9K)
Jun 5, 2026
other
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regul
May 26, 2026
Press
Nanobiotix closed a global offering of 2,218,467 ordinary shares (including ADSs) and 345,099 pre-funded warrants, raisi
Impact 5/10
May 22, 2026
Press
Nanobiotix closed its $100M global offering after underwriters fully exercised their option for 33,805 additional ADSs a
Impact 6/10
Price Targets
$42.69
+24.3% upside
Strong Buy
Current $34.34
Low $29.56
Median $37.56
High $69.82
6 analysts
$29.56
$69.82
Analyst Ratings
4Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| May 1, 2026 | UBS | MAINTAIN | Neutral → Neutral |
| Apr 2, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Feb 6, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $0.04 ▼ -41.4% | $-0.60 — $0.63 | 109% YoY | 4 |
| Next FY | $0.07 ▼ -46.0% | $-0.55 — $1.15 | 59% YoY | 4 |
Latest Reports
NEUTRAL
Press
5/10
Nanobiotix closed a global offering of 2,218,467 ordinary shares (including ADSs) and 345,099 pre-funded warrants, raisi
May 26, 2026
BULLISH
6-K
7/10
Nanobiotix announced Part 1 data from the CONVERGE Phase 2 trial of JNJ-1900 (NBTXR3) in stage 3 inoperable NSCLC, prese
May 18, 2026
BULLISH
6-K
6/10
Nanobiotix announced preclinical data showing that its Nanoprimer technology improves systemic bioavailability and reduc
Apr 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $530.0K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $4.6K | — |
2 institutional holders with $534.6K total value (23,123 shares) as of 2025-Q4. Top holders: MORGAN, WELLS. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 22,923 | $530.0K | 99.1% | DOUBLED +864.0% |
| 2 | WELLS FARGO & COMPANY/MN | 200 | $4.6K | 0.9% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 2,378 | 22,923 | +864.0% | $530.0K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 5,300 | 2,378 | -55.1% | $44.9K | 2025-Q3 |
| UBS Group AG | TRIM | 4,418 | 2,161 | -51.1% | $40.8K | 2025-Q3 |
| UBS Group AG | ADD | 3,000 | 4,418 | +47.3% | $20.9K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 2 | 5,102 | +255000.0% | $14.6K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
BULLISH
6-K
7/10
Nanobiotix announced Part 1 data from the CONVERGE Phase 2 trial of JNJ-1900 (NBTXR3) in stage 3 ino
May 18, 2026
BULLISH
6-K
6/10
Nanobiotix announced preclinical data showing that its Nanoprimer technology improves systemic bioav
Apr 20, 2026
NEUTRAL
6-K
2/10
Nanobiotix filed a routine 6-K disclosing its voting rights and share capital as of March 31, 2026,
Apr 7, 2026
BULLISH
6-K
7/10
Nanobiotix announced first data from a Johnson & Johnson-sponsored Phase 2 trial of JNJ-1900 (NBTXR3
Mar 30, 2026
NEUTRAL
6-K
3/10
Nanobiotix S.A. announced it will release its fourth quarter and full year 2025 financial results on
Mar 26, 2026
NEUTRAL
5/10
Nanobiotix closed a global offering of 2,218,467 ordinary shares (including ADSs) and 345,099 pre-fu
May 26, 2026
MIXED
6/10
Nanobiotix closed its $100M global offering after underwriters fully exercised their option for 33,8
May 22, 2026
BEARISH
6/10
Nanobiotix priced a global follow-on offering of 2,184,662 ordinary shares (including ADSs) and 345,
May 21, 2026
BEARISH
6/10
Nanobiotix priced a global follow-on offering raising ~$98.6M gross ($85M equivalent) via 2,184,662
May 21, 2026
BEARISH
6/10
Nanobiotix has temporarily halted trading on Euronext Paris to finalize allocations and announce pri
May 21, 2026
BEARISH
5/10
Nanobiotix launched a ~€75M (~$87M) global follow-on offering of ADSs and ordinary shares, plus pre-
May 20, 2026
BULLISH
7/10
Nanobiotix announced Part 1 data from the Johnson & Johnson-sponsored Phase 2 CONVERGE study of NBTX
May 17, 2026
NEUTRAL
5/10
Nanobiotix announced FDA acceptance of a protocol amendment to its pivotal NANORAY-312 study for JNJ
May 4, 2026
NEUTRAL
3/10
Nanobiotix S.A. announced it will release its fourth quarter and full-year 2025 financial results on
Mar 26, 2026
NEUTRAL
3/10
Nanobiotix (NBTX) issued a press release denying recent media speculation about a potential takeover
Mar 25, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 4 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$42.69 mean target
+24.3% upside
Strong Buy (1.57)
$29.56 Low
$69.82 High
| Metric | Value |
|---|---|
| Current Price | $34.34 |
| Target Low | $29.56 |
| Target Mean | $42.69 |
| Target Median | $37.56 |
| Target High | $69.82 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.57) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.04 | $-0.60 | $0.63 | 108.5% | -41.4% | 0↑ 1↓ | $0.0B | 34.5% | 4 |
| Next FY 2027-12-31 |
$0.07 | $-0.55 | $1.15 | 59.0% | -46.0% | — | $0.1B | 24.3% | 4 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| May 1, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Apr 2, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 6, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
other
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (A
Jun 2, 2026
earnings
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
<p align="justify">PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3_u4QNy6yvm5c8M
Jun 2, 2026
other
Nanobiotix Joins the Euronext Tech Leaders Index
<p align="justify">PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PA0Z5JS61-nKwtD
May 26, 2026
other
NANOBIOTIX Announces Closing of Global Offering
<p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</str
May 26, 2026
activist
NANOBIOTIX Announces Closing of Global Offering
<p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</str
May 22, 2026
activist
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
<p align="justify">PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</str
May 21, 2026
offering
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
<p align="justify">PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobio
May 21, 2026
offering
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
<p align="justify">PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobio
May 21, 2026
other
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
<p align="justify">PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</str
May 21, 2026
offering
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
<p align="justify">PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</str
May 20, 2026
offering
Nanobiotix Announces Launch of Global Follow-On Offering
<p align="justify">PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</str
May 20, 2026
offering
Nanobiotix Announces Launch of Global Follow-On Offering
<p align="justify">PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</str
May 17, 2026
announcement
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting <pre>Data presented by Johnson &
May 13, 2026
short_interest
FTD: NBTX — 60,117 shares ($2.9M) failed to deliver
Settlement: 20260513, Price: $48.24, FTD Value: $2,900,044.08, NANOBIOTIX S A SPONSORED ADS
May 12, 2026
short_interest
FTD: NBTX — 83,215 shares ($4.5M) failed to deliver
Settlement: 20260512, Price: $53.55, FTD Value: $4,456,163.25, NANOBIOTIX S A SPONSORED ADS